Association between Dyslipidemia and Peritoneal Dialysis Technique Survival by Stepanova, Natalia & Burdeyna, Olena
 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Aug 15; 7(15):2467-2473.                                                                                                                                                2467 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2019 Aug 15; 7(15):2467-2473. 
https://doi.org/10.3889/oamjms.2019.664 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Association between Dyslipidemia and Peritoneal Dialysis 
Technique Survival 
 
 
Natalia Stepanova
*
, Olena Burdeyna 
 
Department of Nephrology and Dialysis, State Institution “Institute of Nephrology of the National Academy of Medical 
Sciences of Ukraine”, Kiev, Ukraine 
 
Citation: Stepanova N, Burdeyna O. Association 
between Dyslipidemia and Peritoneal Dialysis Technique 
Survival. Open Access Maced J Med Sci. 2019 Aug 15; 
7(15):2467-2473.  
https://doi.org/10.3889/oamjms.2019.664 
Keywords: Peritoneal dialysis; Atherogenic dyslipidemia; 
Technique failure; Technique survival; PD adequacy 
*Correspondence: Natalia Stepanova. Department of 
Nephrology and Dialysis, Kiev, Ukraine, State Institution 
“Institute of Nephrology of the National Academy of 
Medical Sciences of Ukraine”. E-mail: 
nmstep88@gmail.com 
Received: 21-Mar-2019; Revised: 02-Jun-2019; 
Accepted: 03-Jun-2019; Online first: 25-Jul-2019 
Copyright: © 2019 Natalia Stepanova, Olena Burdeyna. 
This is an open-access article distributed under the terms 
of the Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC 4.0) 
Funding: The study was carried out within the framework 
of the Institute’s research work: “The Study of New 
Prognostic Risk Factors for Peritoneal Dialysis Technique 
Survival” (Domestic Trial Registration Number is 
0117U002122) 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
 
 
Abstract 
BACKGROUND: A large body of research has investigated the effects of pro-atherogenic lipid profile on 
cardiovascular diseases (CVD) in peritoneal dialysis (PD) patients. However, there is a general lack of research 
on the association between atherogenic dyslipidemia and PD technique survival. 
AIM: The study aimed to define the association between dyslipidemia and PD technique survival. 
METHODS: It was a prospective single-centre observational study involving 40 outpatients on continuous 
ambulatory PD treatment for more than 3 months between 2010 and 2016 in a single centre in Ukraine. There 
were 27 males and 13 females. The mean age of the participants was 49.3 ± 12.2 years. The primary outcome 
measures were all-cause technique failure. 
RESULTS: Atherogenic dyslipidemia was identified in 28/40 (70 %) patients and correlated with PD adequacy 
parameters. During the 36-month- follow-up period technique failure occurred in 2/12 (16.6 %) patients with 
atherogenic dyslipidemia compared with 12 / 28 (42.9 %) patients without atherogenic dyslipidemia (2 = 2.5; p = 
0.12). In the univariate Cox regression model, atherogenic dyslipidemia at baseline was significantly associated 
with a higher risk of all-cause PD technique failure (HR 4.5; 95% CI 1.6 to 12.9; 2 = 5.5, p = 0.019). 
CONCLUSION: The presence of atherogenic dyslipidemia was significantly associated with a higher risk of 
technique failure in PD patients. This is an important issue for future research. Further well-designed clinical trials 
are needed to determine the impact of dyslipidemia on PD adequacy and technique survival. 
 
 
 
 
 
 
 
 
Introduction 
 
End-stage renal disease (ESRD) is a 
worldwide public health problem. The number of 
patients diagnosed with ESRD continues to increase 
considerably from year to year [1], [2]. Peritoneal 
dialysis (PD) is a well-established treatment modality 
for ESRD patients. Currently, in Ukraine, 
approximately 12 % of ESRD patients are maintained 
on PD [3]. Although Ukrainian government and 
healthcare providers continue to focus on increasing 
incident PD use, less attention is focused on the effect 
of time spent on PD therapy and financial resources 
associated with the development of PD technique 
failure. Also, despite the significant progress in 
technique survival, the duration of PD therapy is still 
limited [4], [5].  
There are several factors affecting PD 
technique survival: age, the presence of diabetes, 
residual renal function (RRF), glucose degradation 
products, peritonitis, chronic inflammation, 
cardiovascular diseases (CVD) [5], [6]. Previous 
studies have demonstrated a higher risk of mortality 2 
years after PD treatment compared to the 
hemodialysis (HD) population [7], [8], [9], [10]. CVD 
due to the traditional and non-traditional risk factors 
are the most common causes of death in PD patients 
[9], [11].  
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2468                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
Dyslipidemia is a traditional risk factor of 
cardiovascular events in the general population and 
the HD population [12], [13], [14]. High total 
cholesterol (TC), high levels of low-density lipoprotein 
cholesterol (LDL), very low-density lipoprotein 
cholesterol (VLDL), triglyceride and low level of high-
density lipoprotein cholesterol (HDL) are all well-
known risk factors of developing CVD [13], [14]. It has 
been suggested that patients on PD have differences 
in the lipid profile compared with patients on HD. The 
lipid profile in PD patients is more atherogenic with 
more altered dyslipidemia when compared with those 
in HD patients. This condition may be associated with 
glucose absorption from the peritoneal dialysate, 
peritoneal protein loss and a decrease in residual 
renal function (RRF) [11], [12], [15]. Also, PD 
treatment leads to body weight gain, and it can also 
be a potential risk factor for accelerated 
atherosclerosis [16], [17], [18]. 
A large body of research has investigated the 
effects of pro-atherogenic lipid profile on CVD in PD 
patients [11], [12], [19], [20]. However, in reviewing 
the literature, no data was found on the association 
between atherogenic dyslipidemia and PD technique 
survival and other clinical outcomes including 
parameters of dialysis adequacy in PD patients. It is 
still not clear whether dyslipidemia is associated with 
PD technique survival. We hypothesised that if all 
factors mentioned above associated with dyslipidemia 
in PD patients were the predictors of loss of peritoneal 
function, then dyslipidemia itself could not be 
associated with PD technique survival.  
Therefore, we initiated this prospective 
observational study to determine whether dyslipidemia 
was associated with PD technique failure. 
 
 
Patients and Methods 
 
Study Design and Subjects 
The prospective single-centre observational 
study was carried out between January 2010 and 
September 2016 at State Institution "Institute of 
Nephrology of the National Academy of Medical 
Sciences of Ukraine" in Kyiv, Ukraine. The study was 
conducted following the Declaration of Helsinki. The 
study protocol was confirmed by the Ethics Committee 
of the Institute, and all patients provided their written 
informed consent to participate in the study. Informed 
consent was obtained from all subjects participating in 
the study.  
Forty outpatients with ESRD on PD (27 
males, 13 females) were included in the study. All 
patients were treated with continuous ambulatory PD 
(CAPD) for more than 3 months. They were observed 
to determine the impact of atherogenic lipid profile on 
PD technique survival during the 36-month- follow-
up period.  
All recruited PD patients received 4 
exchanges daily. The diabetics and the patients with a 
history of peritonitis or significant 
illness/hospitalisation were excluded in the previous 3 
months.  
 
 
Methods 
 
Patient demographics data including age, 
gender, comorbid conditions, hypertension and 
dyslipidemia were obtained from medical records.  
Whole blood samples were collected from the 
patients after an overnight fast during a routine 
outpatient visit. The blood samples were processed 
immediately after sampling.  
Routine biochemical parameters including 
blood and daily dialysate concentration of urea and 
creatinine, serum albumin, C-reactive protein (CRP), 
glucose, electrolytes and lipid profile were carried out 
using a Flexor Junior Chemistry Analyzer (Vital 
Scientific, Dieren, Netherlands). Blood lipid profile 
parameters included triglyceride (TG), TC, HDL, LDL 
and VLDL. Atherogenic index of plasma (AIP) was 
calculated from plasma triglyceride and HDL (log [TG / 
HDL]). Body mass index (BMI) was calculated as 
weight in kilograms divided by the square of the height 
in meters.  
Haematological parameters of blood were 
determined using an ABX Micros-60 (ABX 
Diagnostics, Montpelier, France). 
The adequacy of dialysis was determined by 
measuring the total weekly creatinine clearance (CrCl) 
(it was normalized to 1.73 m
2
 of the body surface 
area) and total weekly urea clearance (Kt / V) using 
the Watson formula for calculating body water [21]. 
Peritoneal Kt / V, plasma and renal Kt / V were 
calculated separately. The dialysate/plasma creatinine 
ratio (D / P) was calculated from the concentrations of 
creatinine in 24-h dialysate and plasma [22].  
 
Statistical analysis 
The statistical analysis and all graphs were 
performed using MedCalc (Belgium). The average 
means (M) and the standard deviations (SD) or the 
median (Me) and the interquartile ranges [Q25-Q75] 
were calculated according to the standard normal 
distribution. For the statistical analysis, we used the 
student's t-test and the nonparametric (U-test) Mann-
Whitney U test.  
Categorical variables were expressed as 
proportions. The Chi-square test was used to 
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compare 2 groups. Pearson’s correlation test was 
used to evaluate relationships between lipid profile 
parameters and PD adequacy variables.  
The Kaplan-Meier analysis was used to 
estimate technique survival. The log-rank test was 
used to evaluate the difference in technique survival 
rate according to atherogenic dyslipidemia status. 
The primary endpoint of this study was the 3-
year PD technique survival rate dichotomised 
according to atherogenic dyslipidemia status. PD 
technique failure was defined as discontinuation of PD 
due to uncontrolled volume overload with 2.5% 
dextrose solution or a decrease in total weekly Kt / V 
less than 1.7. Death and kidney transplantation were 
censored. 
Atherogenic dyslipidemia was defined as the 
combination of elevated triglycerides ≥ 2.26 mmol/L (≥ 
200 mg/dL) and HDL levels ≤ 0.9 mmol/L (≤ 80 
mg/dL) in men and ≤ 1.15 mmol/L (≤ 102 mg/dL) in 
women. 
The duration of technique survival was 
calculated from the date of study entry. For this 
analysis, the patients were categorised into 2 groups 
according to atherogenic dyslipidemia presence at 
baseline. Group I consisted of 28 patients with 
atherogenic dyslipidemia and Group II included 12 
patients without atherogenic dyslipidemia. 
The Cox proportional hazards model of 
univariate analysis was used to evaluate the 
association between atherogenic lipid profile and time 
to PD technique failure as well as to estimate the 
Hazard ratios (HR) with 95% Confidence Interval (CI). 
The Cox model was used without adjustment for a 
priori defined confounding variables including age, 
gender, BMI, blood pressure, history of CVD and 
other parameters. P values were calculated, and the 
null hypothesis was rejected if the P-value was < 0.05.  
 
 
Results 
 
Association between dyslipidemia and 
 baseline characteristics 
 Dyslipidemia defined as an increase in 
atherogenic lipoprotein fractions and inhibition of HDL-
cholesterol levels was identified in 28/40 (70%) 
patients. Table 1 shows the baseline characteristics of 
study participants according to the presence of 
atherogenic dyslipidemia. All these data were 
obtained during routine clinical practice immediately 
after enrolling the patients in the study. 
As shown in Table 1, the subjects without 
atherogenic dyslipidemia at baseline were younger 
and less obese. Also, they had lesser systolic blood 
pressure and better glucose control compared with 
those with atherogenic dyslipidemia at baseline. 
Moreover, BMI ratios were directly correlated with 
VLDL levels (r = 0.42, p = 0.007). 
Table 1: Baseline characteristics of the study participants 
according to atherogenic dyslipidemia status 
Clinical parameters All 
(n = 40) 
Absence of 
atherogenic 
dyslipidemia at 
baseline 
(n = 12) 
Presence of 
atherogenic 
dyslipidemia at 
baseline 
(n = 28) 
P 
 
Clinical parameters 
Male gender, n (%) 27 (67.5%) 8 (66.6 %) 19 (67.8 %) 0.9 
Age, years 49.3 ± 12.2 44.6 ± 8.2 52.3 ± 10.4 0.028 
Charlson Comorbidity Index, 
points 
5.57±1.5 4.83 ± 0.8 5.89 ± 1.75 0.06 
BMI, kg/m
2
 25.3 ± 4.3 23.03 ± 1.3 25.07 ± 2.54 0.01 
Serum albumin, g/L 37.1 [34-39] 37.8 [36-40.5] 37 [31.9-39] 0.12 
CRP, mg/L 9.8 [4.3 - 17.2] 9.8 [6.0-21] 10.8 [9.7-17.2] 0.26 
Systolic blood pressure, mm Hg  129 ± 14.2 119 ± 10.2 129.3 ± 14.8 0.03 
Diastolic blood pressure, mm Hg 78 ±12.4 75 ±11.2 79 ± 13.2 0.38 
Hb, g/L 101.8 ±17.6 105.8 [99-124] 104 [94-121] 0.65 
Glucose, mmol/L 5.4 ± 2.1 5.2 [4.8-5.5] 5.9 [4.8-5.1] 0.02 
Ferritin, ng/ml 533 [338.5-832.7] 523 [348.5-822.1] 542 [382-785] 0.58 
Calcium, mmol/L 2.18 [2.0 - 2.33] 2.25 [2.0 - 2.33] 2.11 [2.0-2.27] 0.33 
Phosphorus, mmol/L 1.8 ± 0.5 1.7 ± 0.6 1.8 ± 0,4 0.9 
iPTH, ng/L 225 [123 - 389] 215 [113 - 329] 253 [124-468] 0.11 
Peritoneal dialysis parameters 
Time on PD, months 29 [18.5-37] 17.4 [15.0 – 31.3] 56.0 [32.0-68.1] ˂0.0001 
Urine volume, mL/24 h 570 [320-1200] 920 [680-1300] 450 [400-750] 0.002 
D/P creatinine ratio 0.79 ± 0.08 0.71 ± 0.12 0.78 ± 0.18 0.03 
Low-average transporters, n (%) 11 (27.5%) 4 (33.3%) 7 (25.0%) 0.59 
High-average transporters,n (%) 11 (27.5%) 5 (41.6%) 6 (21.4%) 0.19 
High transporters,n (%) 18 (45.0%) 3 (25.0%) 15 (53.6%) 0.09 
Icodextrin, n (%) 5 (12.5%) 1 (8.3%) 4 (14.3%) 0.60 
Renal weekly Kt/V 0.87 [0.44 - 1.43] 0.91 [0.52 - 1.33] 0.69 [0.22-0.94] 0.06 
Plasma weekly Kt/V 1.46 [1.12 - 1.68] 1.69 [1.32-1.96] 1.35 [1.06-1.62] 0.004 
Total Kt/V 2.26 [1.62-2.84] 2.1 [1.35-2.62] 1.78 [1.6-1.91] 0.11 
CrCl, L/1.73 m
2
 48.2±18.7 49.2 ± 11.05 47.4 ± 7.09 0.02 
Daily peritoneal ultrafiltration, ml 600 [400-830] 600 [400-900] 400 [200-650] 0.01 
Lipid profile parameters 
TC, mmol/L 4.95 [4.1-6.1] 4.9 [4.1-5.8] 5.2 [4.1-6.1] 0.3 
TG, mmol/L 1.58 [1.07 - 2.82] 1.02 [0.85-1.94] 2.45 [1.08-3.32] 0.004 
LDL, mmol/L 2.7 [2.4 - 3.3] 2.6 [2.1-2.9] 2.8 [2.4-3.7] 0.04 
VLDL, mmol/L 0.63 [0.44 - 0.9] 0.7 [0.43-0.8] 1.14 [0.57-1.7] 0.0005 
HDL, mmol/L 1.16 [0.9 - 1.56] 1.25 [0.98-1.3] 0.81 [0.71-1.0] 0.0003 
AIP 3.6 [2.3 - 5.3] 2.9 [2.5-3.15] 4.8 [4.2-5.8] ˂0.0001 
Medications, n (%) 
ACE inhibitors / RAAS blockers 21 (52.5 %) 6 (50.0%) 15 (53.6%) 0.83 
Iron supplementation 19 (47.5 %) 5 (41.6%) 14 (50.0%) 0.63 
Erythropoietins 26 (65.0 %) 7 (58.3%) 19 (67.9%) 0.56 
Beta-blockers 16 (40.0 %) 3 (25%) 13 (46.4%) 0.21 
Calcium channel blockers 28 (70.0 %) 8 (66.6%) 20 (71.4%) 0.76 
Diuretics 15 (37.5 %) 4 (33.3%) 11 (39.3%) 0.72 
Lipid-lowering therapy 12 (30 %) 2 (16.6%) 10 (35.7%) 0.23 
The values are expressed as mean ± standard deviation (M ± SD) or as the median and interquartile range 
(Me [Q25-Q75]). The values are compared between the groups by the Chi-square test, t-test and the Mann–
Whitney U test as appropriate. Abbreviations: AIP, atherogenic index of plasma; ACE, angiotensin-
converting enzyme; BMI, body mass index; CrCl, creatinine clearance; CRP, C-Reactive Protein; Hb, 
hemoglobin; HDL-C, high-density lipoprotein cholesterol; iPTH, intact parathyroid hormone; LDL, low-density 
lipoprotein cholesterol; RAAS, renin-angiotensin-aldosterone system; TC, total cholesterol; total Kt / V, total 
weekly Kt / V urea; VLDL, very low density lipoprotein cholesterol. 
 
Besides, both groups showed significant 
differences in duration of PD therapy, daily urine 
output, dialysate to plasma ratio of creatinine (D/P 
creatinine), plasma weekly Kt/V, weekly creatinine 
clearance and daily peritoneal ultrafiltration.  
 
Correlation analysis of baseline lipid 
 profile with PD adequacy parameters 
Pearson's correlation analysis was performed 
to investigate the correlation between lipid profile and 
PD adequacy variables. It was found that such levels 
as VLDL and HDL and, accordingly, AIP were 
significantly associated with duration of PD treatment: 
r = 0.4, p = 0.009; r = -0.34, p = 0.03 and r = 0.51, p ˂ 
0.0001 (Figure 1), respectively.  
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Figure 1: The correlation between AIP level and duration of PD 
treatment in PD patients 
 
In addition, total weekly Kt/V was negatively 
correlated with serum level of plasma atherogenic 
index (r = -0.35, p = 0.02) and positively correlated 
with HDL (r = 0.35, p = 0.027) in PD patients (Figure 
2). 
 
Figure 2: The correlation between HDL levels and total weekly Kt / 
V in PD patients 
 
The other associations between baseline lipid 
profile and PD adequacy parameters are listed in 
Table 2.  
Table 2: The correlations between lipid profile markers and PD 
adequacy parameters 
PD adequacy  
parameters  
Baseline lipid profile 
TC Triglyceride LDL VLDL HDL AIP 
       
Duration of PD 
therapy 
(months) 
r = 0.16 
p = 0.29 
r = -0.1 
p = 0.53 
r = 0.54 
p = 0.0008 
r = 0.4 
p = 0.009 
r = -0.34 
p = 0.03 
r = 0.51 
p ˂ 0.0001 
Urine volume r = -0.16 
p = 0.15 
r = 0.18 
p = 0.14 
r = -0.31 
p = 0.01 
r = 0.22 
p = 0.21 
r = 0.31 
p = 0.007 
r = 0.15 
p = 0.19 
D / P creatinine 
ratio 
r = 0.13 
p = 0.29 
r = 0.06 
p = 0.65 
r = 0.5 
p = 0.0001 
r = 0.18 
p = 0.16 
r = -0.15, 
p = 0.23 
r = 0.26 
p = 0.04 
Total Kt / V r = -0.13 
p = 0.27 
r = -0.01 
p = 0.93 
r = -0.16 
p = 0.19 
r = -0.13 
p = 0.03 
r = 0.35 
p = 0.027 
r = -0.35 
p = 0.02 
Peritoneal Kt / V r = -0.32 
p = 0.004 
r = -0.05 
p = 0.67 
r = -0.18 
p = 0.15 
r = -0.02 
p = 0.85 
r = 0.4 
p = 0.0005 
r = -0.17 
p = 0.15 
Renal Kt / V r = -0.19 
p = 0.09 
r = -0.03 
p = 0.78 
r = -0.17 
p = 0.17 
r = -0.09 
p = 0.44 
r = 0.27 
p = 0.02 
r = -0.04 
p = 0.69 
Peritoneal CrCl r = -0.33 
p = 0.005 
r = -0.09 
p = 0.94 
r = -0.25 
p = 0.04 
r = -0.05 
p = 0.69 
r = 0.33 
p = 0.006 
r = -0.04 
p = 0.75 
Daily peritoneal 
ultrafiltration 
r = -0.27 
p = 0.01 
r = -0.26 
p = 0.02 
r = -0.12 
p = 0.35 
r = -0.23 
p = 0.053 
r = 0.05 
p = 0.97 
r = -0.19 
p = 0.11 
Abbreviations: AIP, atherogenic index of plasma; CrCl, creatinine clearance; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total 
cholesterol; total Kt / V, total weekly Kt / V urea; VLDL-C, very low-density lipoprotein 
cholesterol. 
There was no correlation between triglyceride 
level and PD adequacy parameters, excluding daily 
peritoneal ultrafiltration volume. However, in contrast, 
baseline HDL level was positively correlated with urine 
output, total weekly Kt/V, peritoneal and renal Kt / V. 
Also, HDL level was negatively correlated with 
duration of PD therapy and D/P creatinine ratio.  
 
 Causes of PD technique failure 
Fourteen of forty (35.0 %) patients 
experienced PD technique failure during the 36-
month- follow-up period: 9/14 (64.3 %) participants 
who were transferred to hemodialysis and 5 patients 
(35.7%) who considered being “technique failures”. 
However, these 5 patients continued PD treatment for 
various reasons: inability of adequate vascular access 
formation-3/5 (60.0%) patients, refusal of HD 
treatment-1/5 (20.0 %) patients, decompensated heart 
failure-1 (20.0%) patient. The main reasons for 
technique failure were the following: dialysis 
inadequacy-7/14 (50.0%) patients, ascribed to 
peritonitis-5/14 (35.7%) patients and non-compliance- 
2/14 (14.3%) patients.  
The incidence of all-cause PD technique 
failure was 2 times higher in the patients with 
atherogenic dyslipidemia compared with the patients 
without dyslipidemia: 2/12 (16.6 %) versus 12/28 (42.9 
%) (Figure 3). However, we did not determine a 
statistically significant difference between the groups 
(
2
 = 2.5; p = 0.12), which might be associated with 
small sample size. 
 
Figure 3: The incidence of all-cause PD technique failure stratified 
according to atherogenic dyslipidemia status 
 
The effect of atherogenic dyslipidemia on 
 all-cause technique failure 
Figure 4 shows the results of the Kaplan-
Meier analysis used to estimate technique survival. 
We observed a highly significant difference in 
technique failure rate in the patients with atherogenic 
dyslipidemia compared with the patients without 
dyslipidemia (log-rank p = 0.02). In the univariate Cox 
regression model, the presence of atherogenic 
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dyslipidemia was significantly associated with a higher 
risk of technique failure (HR 4.5; 95% CI 1.6 to 12.9; 

2
 = 5.5, p = 0.019). 
 
Figure 4: The Kaplan-Meier technique survival curves in PD 
patients dichotomised according to atherogenic dyslipidemia status 
 
 
Discussion 
 
Association between dyslipidemia and 
mortality in PD patients has been well characterized 
[12], [23], [24], [25]. However, there have been no 
reports on the association between pro-atherogenic 
lipid profiles and PD technique survival. To our 
knowledge, this study is the first prospective cohort 
study to compare technique survival in PD patients 
according to atherogenic dyslipidemia status. 
One of the more significant findings to emerge 
from this study is that we found a strong association 
between lipid profile and PD adequacy parameters. 
Moreover, this study also found a significantly higher 
all-cause PD technique failure rate in patients with 
atherogenic dyslipidemia at baseline.  
The effect of dyslipidemia on clinical 
outcomes in PD patients has not been carefully 
addressed. Also, the exact mechanism by which 
dyslipidemia affects a higher risk of all-cause 
technique failure remains unclear. On the other hand, 
the association between pro-atherogenic lipid profile 
and longer PD duration [26], a decrease in RRF [20], 
[27] and glucose absorption from the dialysis fluid 
[28], [29] can be a possible explanation of a higher 
risk of all-cause technique failure. 
Cho et al. reported a statistically significant 
increase in serum TG, AIP and VLDL levels and a 
decrease in serum HDL levels were associated with 
longer PD treatment time while the type of PD solution 
received had no significant effect on these levels [26]. 
Consistent with this notion, we found a strong positive 
correlation between the duration of PD therapy and an 
increase in LDL, VLDL and AIP levels, whereas LDL 
level decreased over the PD treatment time. 
Chen et al. demonstrated different longitudinal 
changes in lipid profiles in PD patients with different 
RRF. They also showed an association between a 
decrease in HDL and deterioration of RRF [20]. LinYC 
et al. analysed the data from a nationwide population-
based cohort study and concluded that the effect of 
lipid profiles on mortality was modified by RRF [30]. In 
the present study, we did not analyse RRF in the 
patients. However, the current study supports the 
results of the findings mentioned above and confirms 
the idea of a positive association between urine 
volume and HDL level. Moreover, we observed a 
significant decrease in residual diuresis in 
dyslipidemia conditions. Additionally, fluid and weight 
control problems are common amongst PD patients 
and may be accompanied by dyslipidemia [16], [20], 
[25], [29], [31]. Rincón et al. found the mean increase 
in fat mass of 3.0 ± 3.2 kg/year during the 26-month-
follow-up period. Changes in fat mass were directly 
associated with an inverse correlation between fat 
mass and HDL in PD patients [28]. Besides, they 
concluded that changes in body composition in 
patients undergoing PD might affect other parameters, 
namely, alteration in lipid profile [28]. We did not 
determine the fat mass in this study. On the other 
hand, we observed an increase in BMI which was 
significantly associated with high levels of VLDL.  
Glucose absorption from the dialysis fluid can 
be considered as an important risk factor for 
increased insulin resistance, enhanced hepatic 
synthesis and secretion of VLDL-C [31]. As a result, 
administration of glucose-based PD solutions leads to 
structural and functional changes in the peritoneal 
membrane resulting in fluid overload, impaired 
glucose control, altered lipid profiles and peritoneal 
dialysis technique failure [23], [32], [33]. This research 
supports previous findings. Thus, we found a direct 
correlation between D/P creatinine ratio and LDL 
levels and an inverse correlation between daily 
peritoneal ultrafiltration and triglyceride level (Table 2). 
We reported total weekly Kt/V urea was associated 
with high levels of LDL and AIP (Table 2).  
It is almost certain that further investigation is 
needed to determine the role of atherogenic 
dyslipidemia in the pathogenesis of PD technique 
failure. Furthermore, inflammation and malnutrition 
can affect lipid levels and PD technique survival [34]. 
However, these factors were not included in the study. 
Our investigation demonstrated a significant 
association between atherogenic dyslipidemia and a 
higher risk of technique failure in PD patients. Thus, it 
becomes possible to hypothesise that lipid-lowering 
therapy can reduce not only CVD risk but also 
improve technique survival in PD patients. 
 
Finally, several important limitations  need 
 to be considered 
First, it was a small sample size study 
performed in a single-centre study. Therefore, our 
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findings revealed only associations. Further study 
with a larger sample size from multiple dialysis 
centres is needed to confirm our results. Second, only 
baseline data were used for this analysis. The current 
study was limited by baseline data. Third, we did not 
investigate the effect of changes in lipid profiles on the 
development of CVD in PD patients during the 
observation period. 
Moreover, dialysis-related, patient-related and 
systemic factors could affect both the development of 
atherosclerosis and PD technique failure. However, 
these factors were not considered in our study. 
Despite the limitations mentioned above, the strong 
association between dyslipidemia and PD technique 
survival observed in the present study indicated the 
important role of dyslipidemia in predicting PD 
technique failure. The larger-scale studies are needed 
for further confirmation of our findings.  
In conclusion, the presence of atherogenic 
dyslipidemia in PD patients was significantly 
associated with a higher risk of technique failure. The 
results of the present study demonstrated that 
dyslipidemia in PD patients could be considered not 
only as a traditional risk factor for CVD but also as a 
predictor of PD technique survival. Further well-
designed clinical trials are needed to determine the 
impact of dyslipidemia on PD adequacy and technique 
survival. 
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